紫花温肺颗粒治疗感染后咳嗽(风寒犯肺证)的疗效与安全性:随机对照试验研究方案
本研究为前瞻性、多中心、随机、双盲、平行组、安慰剂对照试验,计划纳入216例感染后咳嗽(风寒犯肺证)成人患者,随机分为三组:15g活性紫花温肺颗粒组、10g活性颗粒加5g匹配安慰剂组、15g匹配安慰剂组,均每日三次,连续治疗14天。主要结局为咳嗽治愈率和咳嗽缓解率,次要结局包括咳嗽治愈时间、缓解时间、咳嗽症状评分变化、咳嗽视觉模拟评分、中医证候评分、CQLQ变化及不良事件。该试验旨在评估紫花温肺颗粒的疗效与安全性,为感染后咳嗽提供中药治疗证据。
要点
- 紫花温肺颗粒治疗感染后咳嗽(风寒犯肺证)的疗效与安全性尚需随机对照试验验证。
- 试验采用多中心、随机、双盲、安慰剂对照设计,计划纳入216例成人患者。
- 主要结局为咳嗽治愈率和缓解率,治疗周期14天。
核心结论
- 该试验旨在评估紫花温肺颗粒治疗感染后咳嗽(风寒犯肺证)的疗效与安全性,并为中药治疗感染后咳嗽提供证据。
研究设计与样本
- 前瞻性、多中心、随机、双盲、平行组、安慰剂对照试验。
- 计划从中国六家研究中心纳入216例感染后咳嗽成人患者。
- 患者随机分为三组:15g活性紫花温肺颗粒组、10g活性颗粒加5g匹配安慰剂组、15g匹配安慰剂组,均每日三次,连续治疗14天。
主要发现
- 原文未报告试验结果,仅描述研究方案。
关键数值与推荐
- 主要结局为咳嗽治愈率和咳嗽缓解率。
- 次要结局包括咳嗽治愈时间、咳嗽缓解时间、咳嗽症状评分自基线变化、咳嗽视觉模拟评分、第7天和第14天中医证候评分、CQLQ自基线至治疗后的变化以及不良事件。
临床怎么用
- 若试验证实有效,紫花温肺颗粒可能成为感染后咳嗽(风寒犯肺证)的替代治疗选择。
局限性
- 本文为研究方案,尚无结果数据,无法评价疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postinfectious cough usually develops and persists following respiratory tract infection. The protracted cough is embarrassing and troublesome and significantly impairs daily life. However, the optimal treatment available for this condition is still not known. This study aims to investigate the efficacy and safety of a new Chinese herbal prescription, Zihua Wenfei granule (ZHWFG), in treatment of postinfectious cough (wind-cold invading lungs syndrome). METHODS: This study is a prospective, multi-center, randomized, double-blinded, parallel group, placebo-controlled trial. A total of 216 adult participants with postinfectious cough will be enrolled from six study centers across China. All participants are randomly allocated to one of three parallel treatment groups: (1) 15 g of active ZHWFG three times daily, (2) 10 g of active ZHWFG plus 5 g of ZHWFG-matched placebo three times daily, and (3) 15 g of ZHWFG-matched placebo three times daily. The treatment duration is 14 consecutive days. The primary outcomes are cough resolution rate and cough relief rate. Secondary outcomes include time to cough resolution, time to cough relief, change from baseline in cough symptom score, cough visual analog scale value, traditional Chinese medicine syndrome score at days 7 and 14, and change of CQLQ from baseline to post-treatment as well as adverse events. DISCUSSION: This trial may not only investigate the efficacy and safety of ZHWFG in the management of postinfectious cough (wind-cold invading lungs syndrome), but also add the evidence of Chinese herbal medicine in treatment of postinfectious cough and provide an alternative option for the management of postinfectious cough. TRIAL REGISTRATION: ChiCTR1900022078. Registered on 23 March 2019. http://www.chictr.org.cn/showproj.aspx?proj=36547.
引用
- Wang H, She B, Mao B, et al. Efficacy and safety of Zihua Wenfei granules in treatment of postinfectious cough (wind-cold invading lungs syndrome): study protocol for a randomized controlled trial. Trials. 2020. PMID: 32560739. doi:10.1186/s13063-020-04487-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。